

Alpha-1 Antitrypsin Levels and Polymorphisms in Interstitial Lung Diseases

Nalan DEMİR¹, Özlem ERÇEN DİKEN^{2*}, Halil Gürhan KARABULUT³, Demet KARNAK¹, Oya KAYACAN¹

¹Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey

²Department of Chest Diseases, School of Medicine, Hitit University, Çorum, Turkey

³Department of Medical Genetics, School of Medicine, Ankara University, Ankara, Turkey

Received: 14.08.2015 • Accepted/Published Online: 24.07.2016 • Final Version: 18.04.2017

Background/aim: Alpha-1 antitrypsin deficiency may be a potential predisposing factor for interstitial lung fibrosis. We investigated alpha-1 antitrypsin levels and its polymorphisms in patients with interstitial lung disease.

Materials and methods: A total of 103 interstitial lung disease patients were compared.

Results: The mean alpha-1 antitrypsin level in idiopathic interstitial pneumonia patients was 1.67 ± 0.33 g/L, and it was 1.54 ± 0.37 g/L in patients with nonidiopathic interstitial pneumonia ($P = 0.13$). Low alpha-1 antitrypsin levels were more frequently observed in nonidiopathic interstitial pneumonia patients compared with idiopathic interstitial pneumonia, but the difference was not statistically significant (8.9% vs. 0%, respectively, $P = 0.4$). In 100 patients, the normal PiMM genotype was detected, while abnormal ones (PiMZ, $n = 2$, 1.9%; PiMS, $n = 1$, 0.97%) were determined in three cases. When the frequency of alpha-1 antitrypsin polymorphism in interstitial lung disease patients was compared with the data of the healthy population, no significant difference was detected for the PiMZ and PiMS variants ($P = 0.15$ and $P = 0.44$, respectively).

Conclusion: Lower levels of serum alpha-1 antitrypsin were more frequent in nonidiopathic interstitial pneumonia patients than idiopathic interstitial pneumonia without an increase in genetic polymorphism. The difference was not statistically significant.

Key words: Alpha-1 antitrypsin deficiency, idiopathic interstitial pneumonias, interstitial lung disease

1. Introduction

Alpha-1 antitrypsin (α 1-AT) deficiency is a hereditary disorder characterized by a severe decrease in plasma levels of α 1-AT. The condition is associated with a substantially increased risk for the development of pulmonary emphysema by the third or fourth decade of life and is associated with risk of hepatic disease, cutaneous panniculitis, arterial aneurysm, bronchiectasis, and renal disease development. A tentative association with granulomatosis with polyangiitis is also suggested. A number of other conditions, including rheumatoid arthritis and some forms of cancer, have been reported to occur with increased frequency in patients with α 1-AT deficiency (1).

Neutrophil elastase (NE) is the main protease in relation to the development of pulmonary emphysema. In the extracellular space, NE has additional functions such as the regulation of inflammation and it is implicated in inflammatory and fibrotic conditions, including fibrotic lung disease (2,3). The major inhibitor of NE in the lungs is α 1-AT, which limits the local degradation of the

extracellular matrix by migrating cells (4). α 1-AT is a serine protease inhibitor. The gene coding for α 1-AT is located on 14q32.13. Over 75 allelic variations have been reported and classified using the protease inhibitor (PI) nomenclature, which assesses antitrypsin mobility using isoelectric focusing analysis. Mutations are inherited by a simple Mendelian trait; the normal genotype is designated as PiMM, a heterozygote for the Z gene as PiMZ, and a homozygote for the Z gene as PiZZ. The variants are those associated with deficiency, namely the S and Z genes and the uncommon "null" (nonproduction gene) (1). PiM expresses the normal level of α 1-AT in serum (150–350 mg/dL), whereas PiS and PiZ express lower levels of α 1-AT (100–200 mg/dL and 15–50 mg/dL, respectively). It should be kept in mind that serum levels of α 1-AT in PiM and PiS subjects may overlap (5).

The S and Z genes are the most important genes, commonly found in Europeans. About 6% of people of North European descent carry the S gene and 3%–4% carry the Z variant (6,7). In the Turkish population, the frequencies of the α 1-AT alleles, PiMS, PiMZ, and

* Correspondence: oercen@hotmail.com

PiMF, are 70, 72, and 48 per 10,000, respectively (8). Therefore, α 1-AT deficiency is a rare hereditary disorder in asymptomatic healthy people in our country.

α 1-AT deficiency is usually detected initially by measuring the plasma level, followed by specific phenotyping or genotyping.

Elevations in serum elastase have previously been reported in patients with systemic sclerosis (SSc) associated with lung disease (9). It was determined that α 1-AT deficiency contributes to the inflammation and fibrosis in SSc. There are limited data about other interstitial lung disease (ILD) groups such as scleroderma and rheumatoid arthritis, however, and no study covering all types of ILDs has been reported yet. Considering the lung parenchyma destruction in ILDs, a protease/antiprotease imbalance may be a contributing factor. On the basis of recent studies, α 1-AT deficiency could also be a predisposing factor for interstitial fibrosis. Therefore, we conducted a study to determine α 1-AT levels and polymorphisms in ILDs and to evaluate its effect on the clinical and radiological characteristics of such patients with or without α 1-AT deficiency and polymorphism.

2. Materials and methods

A prospective study was conducted with 103 ILD patients older than 18 years of age who had been followed between April 2011 and June 2012 at our university hospital. Subjects with COPD or acute/chronic hepatic disease were excluded.

Demographic features, smoking history, environmental and occupational exposure, comorbidities, pulmonary and extrapulmonary symptoms, physical examination and laboratory findings (whole blood count, routine biochemical analysis, C-reactive protein, erythrocyte sedimentation rate), thorax high-resolution computed tomography (HRCT), spirometry, diffusion capacity of carbon monoxide (DLco), arterial blood gas analysis (ABG), and 6-min walk test distance (6MWD) results were recorded. Venous blood samples were obtained during outpatient clinic admissions. α 1-AT levels were measured in venous blood samples of patients. Genomic DNA was isolated from peripheral blood samples using a spin column method and stored at -20°C until further processing. Genotyping for the α 1-AT polymorphisms was performed by reverse dot blot method. The quantitative determination of α 1-AT in human serum was performed by means of immunonephelometry on the BN^{*} II and BN ProSpec System. The reference range for α 1-AT in human serum is 0.9–2.0 g/L.

Patients with α 1-AT deficiency and/or polymorphism were evaluated in each disease group and investigated for a probable relationship with other factors such as HRCT or echocardiographic findings.

The local institutional ethics committee approved (2012, BAP-project no: 11B3330007) the study and all patients gave informed consent.

2.1. Statistical analyses

All statistical analyses were performed using SPSS 11.0. Demographic data were evaluated by t-test and chi-square test. Chi-square and Fischer exact tests were used for parametric variables. The Mann–Whitney test was used for nonparametric variables. $P < 0.05$ was considered as significant.

3. Results

Sixty-nine female and 34 male patients (total: 103 patients) with ILDs were enrolled in the study. Mean age was 55.81 ± 13.91 years. Thirty-four subjects had a smoking history (6 active smokers, 28 ex-smokers, mean: 28.79 ± 26.18 pack-years). Twenty-five patients had idiopathic interstitial pneumonia (IIP), and 78 with ILDs due to other causes (connective tissue diseases, sarcoidosis, etc.) were grouped as non-IIP subjects (10). The diagnoses of study subjects can be seen in Table 1. Pulmonary symptoms were present in 81 (78.6%) of the patients. The most common symptoms were dyspnea ($n = 56, 54\%$) and cough ($n = 42, 41\%$) (Table 1). The most common physical examination finding was crackles ($n = 59, 57\%$). Thorax HRCT findings are documented in Table 2. Patients had mild hypoxemia (mean partial $\text{O}_2 = 70.79 \pm 15.89$ mmHg), reduced DL_{CO} (mean $\text{DL}_{\text{CO}} (\%) = 71.02 \pm 28.03$), and reduced 6MWD results (mean 6MWD = 425.69 ± 141.16 m).

α 1-AT levels of all subjects ranged between 0.72 and 2.98 g/L. IIP subjects and non-IIP subjects did not differ in respect to mean serum α 1-AT levels (1.67 ± 0.33 g/L vs. 1.54 ± 0.37 g/L, respectively, $P = 0.13$). Seven subjects (6.8%) had serum α 1-AT levels lower than the normal reference range (0.9–2.0 g/L). The subjects with low serum α 1-AT levels were in the non-IIP group (8.9%) and none of the IIP patients had α 1-AT deficiency (0%) ($P = 0.4$). The diagnoses of the patients with α 1-AT deficiency were systemic sclerosis ($n = 3, 2.9\%$), rheumatoid arthritis ($n = 1, 0.9\%$), sarcoidosis ($n = 2, 1.9\%$), and granulomatosis with polyangiitis ($n = 1, 0.9\%$) (Table 3).

Genetic analysis of 100 subjects showed the normal PiMM variant. Three subjects (2.9%) had the α 1-AT heterozygote polymorphism. Two of them (1.9%) with the MZ variant polymorphism had low α 1-AT levels while one with the MS variant had a normal α 1-AT level (0.97%) (Case 1 in Tables 4 and 5). A positive correlation was observed between α 1-AT deficiency and polymorphism ($P = 0.01$). The clinical diagnoses of the patients with α 1-AT polymorphism were systemic sclerosis in two cases (1.9%, PiMZ and PiMS) and sarcoidosis in one (0.9%, PiMZ). The IIP subjects and non-IIP subjects did not differ significantly in respect to the prevalence of α 1-AT polymorphisms ($P = 0.6$) (Tables 3–5).

Table 1. The characteristics of the study group.

	n (%)	Mean
Female/male	69/34 (66.9/3.0)	
Mean age, years		55.81 ± 13.91
Smoking history	34 (33)	28.79 ± 26.18 (pack-years)
History of environmental and occupational exposure (biomass, asbestos, inorganic dust, metal)	20 (19.4)	
Comorbidities	59 (57.2)	
Diagnosis		
IIP*	25 (24.3)	
IPF	14 (13.6)	
NSIP	6 (5.8)	
COP	3 (2.9)	
LIP	1 (1.0)	
RB-ILD	1 (1.0)	
Non-IIP	78 (75.7)	
Connective tissue diseases	54 (52.4)	
♦ Systemic sclerosis	31 (30.1)	
♦ Rheumatoid arthritis	16 (15.5)	
♦ Sjögren's syndrome	3 (2.9)	
♦ Mixed connective tissue disease	2 (1.9)	
♦ Polymyositis/dermatomyositis	1 (1.0)	
Sarcoidosis	15 (14.6)	
Histiocytosis X	3 (2.9)	
Vasculitis	2 (1.9)	
Hypersensitivity pneumonitis	2 (1.9)	
Granulomatosis with polyangiitis	2 (1.9)	
Pulmonary symptoms		
Dyspnea	56 (54.4)	
Cough	42 (40.8)	
Sputum	18 (17.5)	
Chest pain	12 (11.7)	
Mortality	2 (1.9)	

*Idiopathic interstitial pneumonia (IIP) groups: IPF: idiopathic pulmonary fibrosis; NSIP: nonspecific interstitial pneumonia; COP: cryptogenic organizing pneumonia; LIP: lymphoid interstitial pneumonia; RB-ILD: respiratory bronchiolitis-associated interstitial lung disease (n = 25, 24%).

Table 2. Thorax high-resolution computed tomography (HRCT) findings of the patients with interstitial lung disease.

	n (%)
Thorax HRCT findings	58 (56.3)
Ground glass opacity	44 (42.7)
Fibrotic changes	43 (41.7)
Pulmonary nodules	41 (39.8)
Interseptal thickening	40 (38.8)
Mediastinal lymphadenopathy	37 (35.9)
Honeycomb pattern	37 (35.9)
Traction bronchiectasis	31 (30.1)
Reticular changes	21 (20.4)
Hilar lymphadenopathy	16 (15.5)
Linear atelectasis	16 (15.5)
Peribronchial thickening	14 (13.6)
Bullae-cyst	14 (13.6)
Pleural fluid-thickening	12 (11.7)
Subpleural nodules	12 (11.7)
Hyperinflation	11 (10.7)
Mosaic perfusion	8 (7.8)
Intrapulmonary lymph node	7 (6.8)
Consolidation	4 (3.9)
Centrilobular nodules	2 (1.9)
Tree-in-bud	

In this study, the homozygote polymorphism for $\alpha 1$ -AT was not detected in any subject. When compared with the data of the healthy population ($n = 8$), the frequency of $\alpha 1$ -AT polymorphism in study subjects did not differ significantly for the PiMZ and PiMS variants ($P = 0.15$ for PiMZ and $P = 0.44$ for PiMS) (Table 6).

Smoking history, hypoxemia, reduced diffusion capacity, and the presence of pulmonary hypertension on echocardiography (systolic pulmonary arterial pressure ≥ 40 mmHg) did not correlate with $\alpha 1$ -AT deficiency and/or polymorphism in this study ($P > 0.05$). Patients were followed for 2 years. Mortality was not observed in any study subjects.

4. Discussion

Clinical manifestations of $\alpha 1$ -AT deficiency represent two different pathophysiologic processes: protease/antiprotease imbalances as typified by emphysematous lung disease, and the conformational disease typical in the liver.

The potential cellular source of $\alpha 1$ -AT production in the lungs includes epithelial cells, macrophages, and possibly neutrophils. In vitro data indicate not only that lung-derived epithelial cells are capable of $\alpha 1$ -AT production but also that this local production is increased in response to specific inflammatory mediators (11–13). Studies on the peripheral blood mononuclear cells of healthy volunteers show two- to threefold increased secretion of $\alpha 1$ -AT in response to treatment with LPS, IL-1b, and TNF- α (14). These data suggest the important defensive role of locally produced $\alpha 1$ -AT in acute lung inflammation. The lung damage and emphysema resulting from $\alpha 1$ -AT deficiency has traditionally been attributed to unchecked protease activity (15,16). Free neutrophil elastase not only causes direct tissue destruction but also induces the expression of proinflammatory cytokines and neutrophil chemoattractants. However, $\alpha 1$ -AT itself has a potential role in the lung inflammation experienced in $\alpha 1$ -AT-deficient individuals. Formation of complexed and polymerized $\alpha 1$ -AT in the lungs not only exacerbates existing protease/antiprotease imbalances but also potently induces IL-8 expression and attracts neutrophils as a direct conformational effect of the $\alpha 1$ -AT protein (1).

Thus, we suggest that $\alpha 1$ -AT deficiency can be a predisposing factor for interstitial fibrosis and inflammation in ILDs. This study is the first report addressing $\alpha 1$ -AT deficiency in various ILDs.

Increased heterozygote phenotype deficiency in patients with rheumatoid arthritis, juvenile polyarthritis, vasculitis, cutaneous panniculitis, arterial aneurysm, bronchiectasis, and renal disease has been reported (17). A tentative association with granulomatosis with polyangiitis has also been suggested (1). In the present study, among

Table 3. The frequency of $\alpha 1$ -antitrypsin deficiency and polymorphism in patients with idiopathic interstitial pneumonia and nonidiopathic interstitial pneumonia.

Disease groups	Patients with $\alpha 1$ -AT deficiency*	Patients with $\alpha 1$ -AT polymorphism**	
		MZ	MS
IIP (n = 25)	0	0	0
Non-IIP (n = 78)	7	2	1

* $P = 0.4$, ** $P = 0.6$.

$\alpha 1$ -AT: $\alpha 1$ -antitrypsin

IIP: Idiopathic interstitial pneumonia.

Table 4. The patients' characteristics with $\alpha 1$ -antitrypsin deficiency and polymorphism, part 1.

Patients	Age/sex	Diagnosis	Smoking history	HRCT findings
Case 1	20/F	Systemic sclerosis	-	Reticular changes, pulmonary nodules
Case 2	48/F	Systemic sclerosis	-	Pulmonary nodules, interseptal thickening
Case 3	43/M	Granulomatosis with polyangiitis	Ex-smoker (20 pack-years)	Ground glass opacity, fibrotic changes, traction bronchiectasis
Case 4	28/F	Systemic sclerosis	-	Ground glass opacity, traction bronchiectasis, pulmonary nodules
Case 5	73/F	Systemic sclerosis	-	Ground glass opacity, traction bronchiectasis, pulmonary nodules, fibrotic/reticular changes, peribronchial thickening, honeycomb pattern
Case 6	58/F	Rheumatoid Arthritis	-	Ground glass opacity, traction bronchiectasis, honeycomb pattern, interseptal thickening, pulmonary nodules
Case 7	57/F	Sarcoidosis	-	Ground glass opacity, mediastinal/hilar lymphadenopathy, linear atelectasis
Case 8	74/F	Sarcoidosis	-	Mediastinal/hilar lymphadenopathy, pulmonary nodules, interseptal thickening

HRCT: High-resolution computed tomography.

F: Female.

M: Male.

Table 5. The patients' characteristics with $\alpha 1$ -antitrypsin deficiency and polymorphism, part 2.

Patients	Predicted DL _{CO} (%)	sPAP on echo (mmHg)	6MWD (m)	Min SaO ₂ (%) on 6MWD	$\alpha 1$ -AT levels	Genotype of $\alpha 1$ -AT polymorphism
Case 1	83	25	560	97	1.69*	PiMS
Case 2	90	25	520	96.8	0.69	PiMM
Case 3	61	20	656	98	0.72	PiMM
Case 4	72	30	620	96	0.84	PiMM
Case 5	34	40	160	82	0.80	PiMZ
Case 6	102	30	450	95	0.71	PiMM
Case 7	81	35	456	96	0.84	PiMZ
Case 8	89	30	400	95	0.77	PiMM

*Case 1 had a normal $\alpha 1$ -AT level but PiMS polymorphism.

$\alpha 1$ -AT: $\alpha 1$ -antitrypsin (normal reference range: 0.9–2.0 g/L).

DL_{CO}: Diffusing capacity of the lungs for carbon monoxide.

Echo: Echocardiography.

SaO₂: Oxygen saturation.

sPAP: Systolic pulmonary arterial pressure.

6MWD: Six-minute walk distance.

Table 6. The comparison of the frequency of $\alpha 1$ -antitrypsin polymorphism in interstitial lung disease cases with the normal population.

Genotype of $\alpha 1$ -AT polymorphism	Healthy population	Study subjects with ILDs	P-value
PiMM	1164	100	
PiMZ	9	2	0.15
PiMS	7	1	0.44
Total	1203	103	

$\alpha 1$ -AT: $\alpha 1$ -Antitrypsin.

ILD: Interstitial lung disease.

the $\alpha 1$ -AT-deficient subjects, one had rheumatoid arthritis and one had granulomatosis with polyangiitis. However, $\alpha 1$ -AT polymorphisms were not detected in either of them.

In the widely cited study of Geddes et al. (18), patients with rheumatoid arthritis complicated by fibrosing alveolitis were found to be more likely to have abnormal $\alpha 1$ -AT phenotypes than healthy controls. They found a marked increase in the prevalence of the MZ phenotype among patients with cryptogenic fibrosing alveolitis (CFA). Hubbard et al. (19) compared the $\alpha 1$ -AT phenotypes of 189 patients with CFA to 189 age-, sex-, and community-matched controls. In their report, CFA was not associated with abnormal $\alpha 1$ -AT phenotypes. Consistently, none of the 25 IIP patients in the present study had $\alpha 1$ -AT deficiency and/or polymorphism.

Mota et al. evaluated $\alpha 1$ -AT deficiency and/or polymorphism in 27 patients with granulomatosis with polyangiitis (20). They could not observe $\alpha 1$ -AT deficiency compared with the control group while abnormal $\alpha 1$ -AT phenotypes were detected in 5 patients. We detected AT deficiency in 1 patient with granulomatosis with polyangiitis (0.9%). Abnormal $\alpha 1$ -AT phenotypes were not observed in any patient with granulomatosis with polyangiitis.

Barnes et al. (9) examined the role of neutrophil elastase in SSc typified by vascular dysfunction, tissue fibrosis, and inflammation. They found that relative deficiency in serum $\alpha 1$ -AT levels in SSc could have important and pathogenically relevant effects since elastase has proinflammatory and profibrotic roles. They concluded that elastase inhibitors available in clinical practice could serve as potential therapeutic options in SSc. In this first trial showing an association between $\alpha 1$ -AT polymorphism and SSc, 33 SSc subjects were studied and their serum $\alpha 1$ -AT levels were found significantly lower than those of the control group. Similarly, we studied 31 SSc cases and detected $\alpha 1$ -AT deficiency in 3 and $\alpha 1$ -AT polymorphism in 2.

Sarcoidosis has not been related to $\alpha 1$ -AT previously. However, we detected $\alpha 1$ -AT deficiency in two subjects and $\alpha 1$ -AT polymorphism in one with sarcoidosis. To our best knowledge of the literature in English, this is the first report documenting a possible relation of sarcoidosis with $\alpha 1$ -AT deficiency and/or polymorphism.

Simsek et al. (8) determined the prevalence of $\alpha 1$ -AT deficiency in a healthy Turkish population. They documented 0.7% PiMZ and 0.6% PiMS genotypes. In the present study, although $\alpha 1$ -AT polymorphism in ILD patients was more frequent than in the normal population, the difference was not statistically significant. We did not document any homozygote polymorphism in the study subjects, either.

Some subjects with $\alpha 1$ -AT polymorphism may have normal serum levels of $\alpha 1$ -AT. In other words, serum $\alpha 1$ -AT level ranges of various phenotypes of $\alpha 1$ -AT may overlap. Zorzetto et al. (21) reported that the majority of individuals showing $\alpha 1$ -AT levels within the range of 0.93–0.73 mg/dL had PiMS and PiMZ genotypes. However, in our study, we observed these genotypes in 2 out of 7 patients with low $\alpha 1$ -AT levels (0.90–0.72 mg/dL) with a frequency of 43% lower than that reported by Zorzetto et al. This difference may be due to the limited number of cases with $\alpha 1$ -AT deficiency in our study group. $\alpha 1$ -AT levels in individuals with the PiMZ genotype were also given in the range of 0.90–2.10 mg/dL by the American Thoracic Society and European Respiratory Society document (22). These data can explain the normal $\alpha 1$ -AT level found in a patient with the PiMZ genotype in our study.

The relationship between $\alpha 1$ -AT deficiency and chronic obstructive lung disease is well studied; however, the relationship of ILDs with parenchymal destruction and $\alpha 1$ -AT deficiency has not been investigated. Investigating protease and antiprotease balance can lead to further treatment opportunities because pathogenesis is not clear in ILDs. No research has been reported including all ILDs to date. Once the pathologic mechanism is understood, similarly to COPD patients (23), a feasible $\alpha 1$ -AT

replacement could be a life-saving option for patients with ILDs with very limited armamentarium in current practice.

We herein report the first study addressing α 1-AT deficiency and polymorphism in a variety of ILDs including IIP and other ILDs. Our findings have shown that low levels of α 1-AT are found in collagen vascular disease, mainly SSc-related ILDs, and sarcoidosis, but not

in IIP subjects. Large-scale studies are warranted in such patients.

Acknowledgment

This study was supported by the Scientific Research Program of Ankara University (BAP, Project No: 11B3330007).

References

- Mulgrew AT, Taggart CC, McElvaney NG. Alpha-1-antitrypsin deficiency: current concepts. *Lung* 2007; 185: 191-201.
- Pham C. Neutrophil serine proteases fine-tune the inflammatory response. *Int J Biochem Cell Biol* 2008; 40: 1317-1333.
- Chua F, Laurent G. Neutrophil elastase. Mediator of extracellular matrix destruction and accumulation. *Proc Am Thorac Soc* 2006; 3: 424-427.
- Knoell DL, Ralston DR, Coulter KR, Wewers MD. Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-1 β , and tumor necrosis factor- α in monocytes. *Am J Respir Crit Care Med* 1998; 157: 246-255.
- Steiner SJ, Gupta SK, Croffie JM, Fitzgerald JF. Serum levels of α 1-antitrypsin predict phenotypic expression of the α 1-antitrypsin gene. *Dig Dis Sci* 2003; 48: 1793-1796.
- Hutchison DC. Epidemiology of alpha 1-protease inhibitor deficiency. *Eur Respir J* 1990; 9: 29-34.
- de Serres FJ. Worldwide racial and ethnic distribution of α 1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. *Chest* 2002; 122: 1818-1829.
- Simsek H, Pinar A, Altinbas A, Alp A, Balaban YH, Buyukasik Y, Ozcebe O, Hascelik G, Gedikoglu G, Tatar G. Cutoff level to detect heterozygous alpha 1 antitrypsin deficiency in Turkish population. *J Clin Lab Anal* 2011; 25: 296-299.
- Barnes TC, Cross A, Anderson ME, Edwards SW, Moots RJ. Relative α 1-anti-trypsin deficiency in systemic sclerosis. *Rheumatology (Oxford)* 2011; 50: 1373-1378.
- Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013; 188: 733-748.
- Cichy J, Potempa J, Travis J. Biosynthesis of α 1-proteinase inhibitor by human lung-derived epithelial cells. *J Biol Chem* 1997; 272: 8250-8255.
- Boutten A, Venembre P, Seta N, Hamelin J, Aubier M, Durand G, Dehoux MS. Oncostatin M is a potent stimulator of α 1-antitrypsin secretion in lung epithelial cells: modulation by transforming growth factor-beta and interferon-gamma. *Am J Respir Cell Mol Biol* 1998; 18: 511-520.
- Kalsheker N, Morley S, Morgan K. Gene regulation of the serine proteinase inhibitors α 1-antitrypsin and α 1-antichymotrypsin. *Biochem Soc Trans* 2002; 30: 93-98.
- Knoell DL, Ralston DR, Coulter KR, Wewers MD. Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-1 β , and tumor necrosis factor- α in monocytes. *Am J Respir Crit Care Med* 1998; 157: 246-255.
- Elliott PR, Bilton D, Lomas DA. Lung polymers in Z α 1-antitrypsin deficiency-related emphysema. *Am J Respir Cell Mol Biol* 1998; 18: 670-674.
- Gadek JE, Pacht ER. The protease-antiprotease balance within the human lung: implications for the pathogenesis of emphysema. *Lung* 1990; 168: 552-564.
- Fallat RJ. Reactive airways disease and α 1-antitrypsin deficiency. In: Crystal RG, editor. *Alpha1-antitrypsin Deficiency*. 1st ed. New York, NY, USA: Marcel Dekker; 1996. pp. 259-279.
- Geddes DM, Webley M, Brewerton DA, Turton CW, Turner-Warwick M, Murphy AH, Ward AM. α 1-Antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. *Lancet* 1977; 19: 1049-1051.
- Hubbard R, Baoku Y, Kalsheker N, Britton J, Johnston I. Alpha1-antitrypsin phenotypes in patients with cryptogenic fibrosing alveolitis: a case-control study. *Eur Respir J* 1997; 10: 2881-2883.
- Mota A, Sahebghadam Lotfi A, Jamshidi AR, Najavand S. Alpha 1-antitrypsin activity is markedly decreased in Wegener's granulomatosis. *Rheumatol Int* 2014; 34: 553-558.
- Zorzetto M, Russi E, Senn O, Imboden M, Ferrarotti I, Tinelli C, Campo I, Ottaviani S, Scabini R, von Eckardstein A et al. *SERPINA1* gene variants in individuals from the general population with reduced α 1-antitrypsin concentrations. *Clin Chem* 2008; 54: 1331-1338.
- American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. *Am J Respir Crit Care Med* 2003; 168: 818-900.
- Chorostowska-Wynimko J. Disease modification in emphysema related to alpha-1 antitrypsin deficiency. *COPD* 2016; 12: 1-9.